Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Netscientific (NSCI) Share News

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

16th Aug 2024 20:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More

NetScientific loss narrows; assets under management top GBP100 million

13th Jun 2024 14:33

(Alliance News) - NetScientific PLC on Thursday said it was optimistic about 2024 as it hailed a milestone in assets under management amid a narrowed loss. Read More

TRADING UPDATES: NetScientific backs Wanda; Inspirit Energy wins deal

28th May 2024 20:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Vertu Motors ups dividend as hails record revenue

15th May 2024 18:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake

13th May 2024 18:55

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: NetScientific says PDS Biotech's Versamune meets endpoints

10th May 2024 13:19

NetScientific PLC - London-based deep tech and life sciences venture capital investor - Says its portfolio company, PDS Biotechnology Corp's Versamune meets endpoints in a phase three trial for patients with HPV. NetScientific holds a 3.5% shareholding in PDS. Versamune is a T cell-activating platform that effectively stimulates a precise immune system response to a cancer-specific protein. Read More

NetScientific investee secures funding to develop product range

15th Apr 2024 11:06

(Alliance News) - NetScientific PLC on Monday said its portfolio company ProAxsis Ltd secured GBP1.8 million in investment. Read More

TRADING UPDATES: Empire Metals targets key milestones in Australia

27th Mar 2024 18:47

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

NetScientific "significantly" advances strategic goals

13th Mar 2024 17:04

(Alliance News) - NetScientific PLC on Wednesday released a portfolio and strategy update. Read More

TRADING UPDATES: Esken's Southend Airport faces further allegations

23rd Jan 2024 18:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: NetScientific investee DeepTech Recycling bags GBP1 million

1st Dec 2023 11:59

NetScientific PLC - technology and life sciences investor - Portfolio company DeepTech Recycling Ltd closes GBP1 million fundraising. DeepTech, in which NetScientific holds a 30% stake, is a company focused on chemical recycling of plastic waste. Last December, it bought the assets of Recycling Technologies Ltd out of administration. The fundraise is carried out via an advance share subscription agreement and is the first closing of a target investment programme of around GBP3 million, with further investment anticipated within the next six months. Read More

IN BRIEF: NetScientific's portfolio company updates on cancer trial

9th Nov 2023 19:41

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor - Read More

IN BRIEF: NetScientific says Ventive on fire with new investment

6th Nov 2023 12:00

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor - Says portfolio company Ventive, a London-based designer and manufacturer of heating and ventillation solutions, has successfuly closed a new investment of around GBP900,000. Funding included GBP316,000 from existing shareholders and the conversion of two existing convertible loans valued at about GBP600,000. Investment is part of Ventive's proposed GBP1 million to GBP1.5 million programme, with further investments expected by April 30. NetScientific now holds an 11% total equity stake in Ventive, with a post-investment fair value of GBP893,000 - up from GBP52,000 at December 31. Read More

NetScientific investee claims promising results in biomarker study

23rd Oct 2023 21:10

(Alliance News) - NetScientific PLC on Monday said its investee PDS Biotechnology Corp was "encouraged" by study data for its PDS0101 combined with Merck & Co Inc's drug Keytruda. Read More

IN BRIEF: NetScientific portfolio company updates on cancer trial

3rd Oct 2023 17:12

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investment company - Reports that its portfolio company, PDS Biotechnology Corp, has announced updated interim data from the Versatile-002 phase two clinical trial evaluating PDS0101 in combination with Merck & Co Inc's Keytruda in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma. Read More

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

28th Sep 2023 14:24

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

NetScientific's Q-Bot completes GBP3.5 million investment programme

13th Sep 2023 21:32

(Alliance News) - NetScientific PLC on Wednesday said that its portfolio company, Q-Bot, has successfully closed a GBP3.5 million investment programme. Read More

IN BRIEF: NetScientific's PDS suffers wider loss as R&D costs mount

14th Aug 2023 19:49

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Portfolio company PDS Biotechnology Corp reports results for the quarter to June 30. Net loss was USD11.5 million, widened from USD5.8 million the year before. Higher loss primarily due to costs incurred in connection with research and development programmes, which more than doubled to USD8.0 million from USD3.8 million. Loss per share of USD0.37 compared to USD0.20 before. Further, PDS reports the successful submission of final clinical protocol and supporting information to the US Food & Drug Administration to initiate phase 3 Versatile-003 trial in the fourth quarter. Adds biomarker data from Versatile-002 will be presented at the European Society for Medical Oncology Congress. Read More

TRADING UPDATES: Pendragon quarterly trading momentum maintained

30th Jun 2023 14:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

TRADING UPDATES: tinyBuild bemoans disappointing interim performance

29th Jun 2023 14:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,809.74
Change53.53